2.44
0.09 (3.83%)
| 前收盘价格 | 2.35 |
| 收盘价格 | 2.25 |
| 成交量 | 20 |
| 平均成交量 (3个月) | 219 |
| 市值 | 1,546,830,720 |
| 52周波幅 | |
| 利润日期 | 10 Apr 2025 |
| 营业毛利率 | -203.39% |
| 营业利益率 (TTM) | -127.07% |
| 稀释每股收益 (EPS TTM) | -0.010 |
| 季度收入增长率 (YOY) | -6.10% |
| 总债务/股东权益 (D/E MRQ) | 5.84% |
| 流动比率 (MRQ) | 3.95 |
| 营业现金流 (OCF TTM) | -2.92 M |
| 杠杆自由现金流 (LFCF TTM) | 1.19 M |
| 资产报酬率 (ROA TTM) | -7.35% |
| 股东权益报酬率 (ROE TTM) | -38.52% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (GB) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 看跌 | |
| 股票 | RELIEF THERAPEUTICS HOLDING SA | - | - |
AIStockmoo 评分
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 4.0 |
| 平均 | 0.50 |
相关股票
| 股票 | 市值 | DY | P/E（TTM） | P/B |
|---|---|---|---|---|
| RELIEF THERAPEUTICS HOLDING SA | 2 B | - | - | - |
| ARROWHEAD PHARMACEUTICALS INC A | 2 B | - | - | - |
| IDORSIA LTD IDORSIA N ORD SHS | 1 B | - | - | - |
| OXFORD NANOPORE TECHNOLOGIES PL | 1 B | - | - | 2.97 |
| BASILEA PHARMACEUTICA AG BASILE | 560 M | - | - | - |
| IOVANCE BIOTHERAPEUTICS INC IOV | 401 M | - | - | - |
|
Relief Therapeutics Holding SA is engaged in the research, development, and commercialization of biopharmaceutical products. It mainly develops drugs of natural human origin. It has a focus on commercial products, and the development program pipeline is focused on three main areas: rare genetic, metabolic disorders, rare connective tissue disorders, and rare lung diseases. Its pipeline includes various drug candidates in their different stages of development, such as RLF-TD011 and RLF-100, among others. It also has commercial legacy products like Cambia, Setofilm, Voltadol, and Voltfast, among others. Geographically, the company generates a majority of its revenue from Europe (excluding Switzerland) and the rest from North America, Switzerland, and the rest of the world. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 1.00% |
| 机构持股比例 | 23.11% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合